Drug Discovery Services Market by Process (Target Selection, Validation, Lead Optimization), Type (Medicinal Chemistry, DMPK), Drug Type (Biologics, Small Molecules), Therapeutic (Oncology, Neurology), Company (Tier 1, 2, 3) - Global Forecast to 2025

Table of Contents

1.... INTRODUCTION

1.1             OBJECTIVES OF THE STUDY
1.2             MARKET DEFINITION
1.3             MARKET SCOPE
1.3.1              MARKETS COVERED.. 21
1.3.2              YEARS CONSIDERED FOR THE STUDY
1.4             CURRENCY
1.5             LIMITATIONS
1.6             STAKEHOLDERS

2.... RESEARCH METHODOLOGY

2.1             RESEARCH DATA
2.1.1              SECONDARY DATA
2.1.1.1            KEY DATA FROM SECONDARY SOURCES
2.1.2              PRIMARY DATA
2.2             MARKET SIZE ESTIMATION
2.2.1              MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
2.2.2              MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
2.2.3              GROWTH FORECAST. 27
2.3             MARKET BREAKDOWN AND DATA TRIANGULATION
2.4             ASSUMPTIONS FOR THE STUDY

3.... EXECUTIVE SUMMARY

4.... PREMIUM INSIGHTS

4.1             DRUG DISCOVERY SERVICES MARKET OVERVIEW
4.2             NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE & COUNTRY (2020)
4.3             DRUG DISCOVERY SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5.... MARKET OVERVIEW

5.1             INTRODUCTION
5.2             MARKET DYNAMICS
5.2.1              DRIVERS
5.2.1.1            GROWING R&D EXPENDITURE IN THE PHARMACEUTICAL & BIOPHARMACEUTICAL INDUSTRY
5.2.1.2            INCREASING DEMAND FOR OUTSOURCING ANALYTICAL TESTING AND CLINICAL
TRIAL SERVICES
5.2.1.3            INITIATIVES FOR RESEARCH ON RARE DISEASES AND ORPHAN DRUGS
5.2.1.4            FOCUS ON DRUG DISCOVERY
5.2.2              RESTRAINTS
5.2.2.1            HIGH COST OF DRUG DISCOVERY AND DEVELOPMENT
5.2.2.2            STRINGENT REGULATIONS GOVERNING DRUG DISCOVERY AND ANIMAL USAGE
5.2.3              OPPORTUNITIES
5.2.3.1            GROWTH IN THE BIOLOGICS MARKET
5.2.3.2            PATENT EXPIRIES
5.2.3.3            EMERGING MARKETS
5.2.4              TRENDS
5.2.4.1            GROWING ADOPTION OF ARTIFICIAL INTELLIGENCE-BASED TOOLS FOR
DRUG DISCOVERY

6.... DRUG DISCOVERY SERVICES MARKET, BY PROCESS

6.1             INTRODUCTION
6.2             TARGET SELECTION
6.2.1              INCREASING DEMAND FOR PERSONALIZED MEDICINE TO SUPPORT
THE GROWTH OF THIS MARKET
6.3             TARGET VALIDATION
6.3.1              RISING NUMBER OF DRUG DISCOVERY RESEARCH ACTIVITIES TO SUPPORT MARKET GROWTH
6.4             HIT-TO-LEAD IDENTIFICATION
6.4.1              HIT-TO-LEAD IDENTIFICATION IS THE LARGEST PROCESS SEGMENT IN
THE MARKET
6.5             LEAD OPTIMIZATION
6.5.1              LEAD OPTIMIZATION REQUIRES STATE-OF-THE-ART INFORMATICS SYSTEMS TO FACILITATE TRANSPARENT PRESENTATION AND ANALYSIS
6.6             CANDIDATE VALIDATION
6.6.1              CANDIDATE VALIDATION SEGMENT TO GROW AT A HIGH CAGR DURING
THE FORECAST PERIOD

7.... DRUG DISCOVERY SERVICES MARKET, BY TYPE

7.1             INTRODUCTION
7.2             MEDICINAL CHEMISTRY SERVICES
7.2.1              WIDE APPLICATIONS OF MEDICINAL CHEMISTRY IN DRUG DISCOVERY ARE A MAJOR FACTOR DRIVING MARKET GROWTH
7.3             BIOLOGY SERVICES
7.3.1              RESTRICTIONS ON THE USAGE OF ANIMALS IN RESEARCH ACTIVITIES MAY LIMIT MARKET GROWTH
7.4             DRUG METABOLISM & PHARMACOKINETICS.. 57
7.4.1              DMPK STUDIES ARE EMPLOYED AT THE DISCOVERY, CANDIDATE SELECTION, INVESTIGATIONAL NEW DRUG, AND NEW DRUG APPLICATION STAGES

8.... DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE

8.1             INTRODUCTION
8.2             SMALL-MOLECULE DRUGS
8.2.1              INCREASING NUMBER OF START-UPS AND NEW ENTRANTS IN THE SMALL-MOLECULE DRUGS SEGMENT WILL DRIVE THE GROWTH OF THIS MARKET DURING THE FORECAST PERIOD
8.3             BIOLOGIC DRUGS
8.3.1              HIGH SET-UP COSTS OF THE INSTRUMENTS REQUIRED FOR BIOLOGIC DRUG MANUFACTURING MAY LIMIT MARKET GROWTH TO A CERTAIN EXTENT

9.... DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA

9.1             INTRODUCTION
9.2             ONCOLOGY
9.2.1              HIGH AND GROWING NUMBER OF RESEARCH STUDIES ON CANCER THERAPEUTICS TO SUPPORT MARKET GROWTH.. 64
9.3             NEUROLOGY
9.3.1              INCREASING NUMBER OF PATIENTS SUFFERING FROM NEUROLOGICAL DISORDERS IS DRIVING MARKET GROWTH
9.4             INFECTIOUS AND IMMUNE SYSTEM DISEASES.. 67
9.4.1              EMERGENCE OF NEW INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
9.5             DIGESTIVE SYSTEM DISEASES
9.5.1              AS THERE IS A HUGE POPULATION SEEKING EFFECTIVE REMEDIES FOR DIGESTIVE DISEASES, PHARMACEUTICAL COMPANIES ARE INVESTING SIGNIFICANTLY IN R&D FOR THE DEVELOPMENT OF INNOVATIVE DRUGS
9.6             CARDIOVASCULAR DISEASES
9.6.1              HIGH GLOBAL BURDEN OF CARDIOVASCULAR DISEASES HAS INCREASED THE FOCUS ON DEVELOPING EFFECTIVE DRUGS
9.7             OTHER THERAPEUTIC AREAS

10.. DRUG DISCOVERY SERVICES MARKET, BY COMPANY TYPE

10.1          INTRODUCTION
10.2          TIER 1 PHARMACEUTICAL COMPANIES
10.3          TIER 2 PHARMACEUTICAL COMPANIES
10.4          TIER 3 PHARMACEUTICAL COMPANIES

11.. DRUG DISCOVERY SERVICES MARKET, BY REGION

11.1          INTRODUCTION
11.2          NORTH AMERICA
11.2.1            US
11.2.1.1          AVAILABILITY OF ADVANCED R&D INFRASTRUCTURE HAS DRIVEN THE GROWTH OF THE US MARKET
11.2.2            CANADA
11.2.2.1          PREFERENCE OF PHARMACEUTICAL COMPANIES TO CONDUCT CLINICAL TRIALS IN CANADA TO SUPPORT MARKET GROWTH

11.3          EUROPE
11.3.1            GERMANY
11.3.1.1          GOVERNMENT SUPPORT AND FLEXIBLE LABOR LAWS ARE DRIVING THE GROWTH OF THE GERMAN DRUG DISCOVERY SERVICES MARKET
11.3.2            UK
11.3.2.1          INVESTMENT BY PHARMACEUTICAL SPONSORS IN THE UK FOR DRUG DISCOVERY SERVICES TO SUPPORT MARKET GROWTH
11.3.3            FRANCE
11.3.3.1          HIGH NUMBER OF ONCOLOGY CLINICAL TRIALS IN FRANCE TO DRIVE
MARKET GROWTH
11.3.4            ITALY
11.3.4.1          HIGH NUMBER OF CLINICAL TRIALS AND THE LOW DRUG APPROVAL TIME ARE
THE MAJOR FACTORS DRIVING MARKET GROWTH
11.3.5            SPAIN
11.3.5.1          SHORT STUDY START-UP TIMES AND RISING R&D EXPENDITURE TO BOOST
THE GROWTH OF THE SPANISH MARKET
11.3.6            REST OF EUROPE
11.4          ASIA PACIFIC
11.4.1            CHINA
11.4.1.1          LOW COST OF CLINICAL TRIALS AND LARGE PHARMACEUTICAL R&D FOOTPRINT IN CHINA TO DRIVE MARKET GROWTH
11.4.2            INDIA
11.4.2.1          LOW-COST SERVICES AND AVAILABILITY OF SKILLED WORKFORCE TO SUPPORT MARKET GROWTH IN INDIA
11.4.3            JAPAN
11.4.3.1          GOVERNMENT INITIATIVES FOR DRUG INNOVATION TO SUPPORT MARKET GROWTH IN JAPAN
11.4.4            REST OF ASIA PACIFIC
11.5          REST OF THE WORLD

12.. COMPETITIVE LANDSCAPE

12.1          OVERVIEW
12.2          MARKET SHARE ANALYSIS
12.3          COMPETITIVE SCENARIO
12.3.1            PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS
12.3.2            SERVICE LAUNCHES.. 120
12.3.3            MERGERS & ACQUISITIONS
12.3.4            EXPANSIONS
12.4          COMPETITIVE LEADERSHIP MAPPING
12.4.1            VISIONARY LEADERS
12.4.2            INNOVATORS
12.4.3            DYNAMIC DIFFERENTIATORS
12.4.4            EMERGING COMPANIES

13.. COMPANY PROFILES

(BUSINESS OVERVIEW, SERVICES OFFERED, RECENT DEVELOPMENTS, MNM VIEW)*
13.1          LABORATORY CORPORATION OF AMERICA HOLDINGS
13.2          EUROFINS SCIENTIFIC SE
13.3          CHARLES RIVER LABORATORIES INTERNATIONAL
13.4          EVOTEC SE
13.5          THERMO FISHER SCIENTIFIC
13.6          ALBANY MOLECULAR RESEARCH, INC.
13.7          SYNGENE INTERNATIONAL LIMITED
13.8          JUBILANT LIFESCIENCES
13.9          GENSCRIPT BIOTECH CORPORATION
13.10        PIRAMAL ENTERPRISES LIMITED
13.11        SELVITA S.A.
13.12        AURIGENE DISCOVERY TECHNOLOGIES
(A SUBSIDIARY OF DR. REDDY’S LABORATORIES)
13.13        DOMAINEX LTD.
13.14        WUXI APPTEC
13.15        CHEMPARTNER CO., LTD.
13.16        FRONTAGE HOLDINGS
13.17        PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC
13.18        SHANGHAI MEDICILON, INC.
13.19        TCG LIFESCIENCES PVT. LIMITED
13.20        VIVA BIOTECH (SHANGHAI) LTD.
*BUSINESS OVERVIEW, SERVICES OFFERED, RECENT DEVELOPMENTS, MNM VIEW MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.
14.. APPENDIX

LIST OF TABLES

TABLE 1              DRUG DISCOVERY PROCESS OVERVIEW
TABLE 2              RESEARCH PROJECTS FUNDED BY THE IRDIRC
TABLE 3              AVERAGE COST OF DRUGS APPROVED PER YEAR, 2004–2013
TABLE 4              DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2018–2025 (USD MILLION)
TABLE 5              DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY REGION, 2018–2025 (USD MILLION)
TABLE 6              ADVANTAGES AND DISADVANTAGES OF SIRNA
TABLE 7              DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY REGION, 2018–2025 (USD MILLION)
TABLE 8              DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION,
BY REGION, 2018–2025 (USD MILLION)
TABLE 9              DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY REGION, 2018–2025 (USD MILLION)
TABLE 10            DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY REGION, 2018–2025 (USD MILLION)
TABLE 11            DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 12            MEDICINAL CHEMISTRY DRUG DISCOVERY SERVICES MARKET, BY REGION,
2018–2025 (USD MILLION)
TABLE 13            BIOLOGY DRUG DISCOVERY SERVICES MARKET, BY REGION,
2018–2025 (USD MILLION)
TABLE 14            DMPK DRUG DISCOVERY SERVICES MARKET, BY REGION,
2018–2025 (USD MILLION)
TABLE 15            DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2018–2025 (USD MILLION)
TABLE 16            DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY REGION, 2018–2025 (USD MILLION)
TABLE 17            DRUG DISCOVERY SERVICES MARKET FOR BIOLOGIC DRUGS, BY REGION,
2018–2025 (USD MILLION)
TABLE 18            GLOBAL NUMBER OF CLINICAL TRIALS, BY THERAPEUTIC AREA
(AS OF OCTOBER 2019)
TABLE 19            DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD MILLION)
TABLE 20            DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY REGION,
2018–2025 (USD MILLION)
TABLE 21            DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGY, BY REGION,
2018–2025 (USD MILLION)
TABLE 22            DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS AND IMMUNE SYSTEM DISEASES, BY REGION, 2018–2025 (USD MILLION)
TABLE 23            DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES,
BY REGION, 2018–2025 (USD MILLION)
TABLE 24            DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES,
BY REGION, 2018–2025 (USD MILLION)
TABLE 25            DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS,
BY REGION, 2018–2025 (USD MILLION)
TABLE 26            DRUG DISCOVERY SERVICES MARKET, BY COMPANY TYPE,
2018–2025 (USD MILLION)

TABLE 27            DRUG DISCOVERY SERVICES MARKET FOR TIER 1 PHARMACEUTICAL COMPANIES, BY REGION, 2018–2025 (USD MILLION)
TABLE 28            DRUG DISCOVERY SERVICES MARKET FOR TIER 2 PHARMACEUTICAL COMPANIES, BY REGION, 2018–2025 (USD MILLION)
TABLE 29            DRUG DISCOVERY SERVICES MARKET FOR TIER 3 PHARMACEUTICAL COMPANIES, BY REGION, 2018–2025 (USD MILLION)
TABLE 30            DRUG DISCOVERY SERVICES MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 31            NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY,
2018–2025 (USD MILLION)
TABLE 32            NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2018–2025 (USD MILLION)
TABLE 33            NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2018–2025 (USD MILLION)
TABLE 34            NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2018–2025 (USD MILLION)
TABLE 35            NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2025 (USD MILLION)
TABLE 36            NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY COMPANY TYPE, 2018–2025 (USD MILLION)
TABLE 37            NUMBER OF CLINICAL TRIALS STARTED IN THE US, BY COMPANY, 2017
TABLE 38            US: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2018–2025 (USD MILLION)
TABLE 39            US: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 40            US: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2018–2025 (USD MILLION)
TABLE 41            US: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD MILLION)
TABLE 42            NUMBER OF ACTIVE CLINICAL TRIALS IN CANADA, BY CONDITION (2019)
TABLE 43            NUMBER OF ACTIVE CLINICAL TRIALS IN CANADA, BY COMPANY, 2017
TABLE 44            CANADA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2018–2025 (USD MILLION)
TABLE 45            CANADA: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2018–2025 (USD MILLION)
TABLE 46            CANADA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2018–2025 (USD MILLION)
TABLE 47            CANADA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD MILLION)
TABLE 48            EUROPE: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY,
2018–2025 (USD MILLION)
TABLE 49            EUROPE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2018–2025 (USD MILLION)
TABLE 50            EUROPE: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2018–2025 (USD MILLION)
TABLE 51            EUROPE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2018–2025 (USD MILLION)
TABLE 52            EUROPE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD MILLION)
TABLE 53            EUROPE: DRUG DISCOVERY SERVICES MARKET, BY COMPANY TYPE,
2018–2025 (USD MILLION)

TABLE 54            GERMANY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2018–2025 (USD MILLION)
TABLE 55            GERMANY: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2018–2025 (USD MILLION)
TABLE 56            GERMANY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2018–2025 (USD MILLION)
TABLE 57            GERMANY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD MILLION)
TABLE 58            UK: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2018–2025 (USD MILLION)
TABLE 59            UK: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 60            UK: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2018–2025 (USD MILLION)
TABLE 61            UK: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD MILLION)
TABLE 62            NUMBER OF CLINICAL TRIALS STARTED IN FRANCE, BY COMPANY, 2017
TABLE 63            FRANCE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2018–2025 (USD MILLION)
TABLE 64            FRANCE: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2018–2025 (USD MILLION)
TABLE 65            FRANCE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2018–2025 (USD MILLION)
TABLE 66            FRANCE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD MILLION)
TABLE 67            NUMBER OF CLINICAL TRIALS STARTED IN ITALY, BY COMPANY, 2017
TABLE 68            ITALY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2018–2025 (USD MILLION)
TABLE 69            ITALY: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 70            ITALY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2018–2025 (USD MILLION)
TABLE 71            ITALY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD MILLION)
TABLE 72            SPAIN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2018–2025 (USD MILLION)
TABLE 73            SPAIN: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2018–2025 (USD MILLION)
TABLE 74            SPAIN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2018–2025 (USD MILLION)
TABLE 75            SPAIN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD MILLION)
TABLE 76            ROE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2018–2025 (USD MILLION)
TABLE 77            ROE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 78            ROE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2018–2025 (USD MILLION)
TABLE 79            ROE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD MILLION)
TABLE 80            TOTAL NUMBER OF CLINICAL TRIALS IN APAC, BY THERAPEUTIC AREA, 2017

TABLE 81            APAC: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY,
2018–2025 (USD MILLION)
TABLE 82            APAC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2018–2025 (USD MILLION)
TABLE 83            APAC: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 84            APAC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2018–2025 (USD MILLION)
TABLE 85            APAC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD MILLION)
TABLE 86            APAC: DRUG DISCOVERY SERVICES MARKET, BY COMPANY TYPE,
2018–2025 (USD MILLION)
TABLE 87            CHINA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2018–2025 (USD MILLION)
TABLE 88            CHINA: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2018–2025 (USD MILLION)
TABLE 89            CHINA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2018–2025 (USD MILLION)
TABLE 90            CHINA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD MILLION)
TABLE 91            INDIA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2018–2025 (USD MILLION)
TABLE 92            INDIA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 93            INDIA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2018–2025 (USD MILLION)
TABLE 94            INDIA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD MILLION)
TABLE 95            JAPAN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2018–2025 (USD MILLION)
TABLE 96            JAPAN: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2018–2025 (USD MILLION)
TABLE 97            JAPAN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2018–2025 (USD MILLION)
TABLE 98            JAPAN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD MILLION)
TABLE 99            ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2018–2025 (USD MILLION)
TABLE 100          ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY TYPE,
2018–2025 (USD MILLION)
TABLE 101          ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2018–2025 (USD MILLION)
TABLE 102          ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD MILLION)
TABLE 103          ROW: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2018–2025 (USD MILLION)
TABLE 104          ROW: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 105          ROW: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2018–2025 (USD MILLION)
TABLE 106          ROW: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2018–2025 (USD MILLION)

TABLE 107          ROW: DRUG DISCOVERY SERVICES MARKET, BY COMPANY TYPE,
2018–2025 (USD MILLION)
TABLE 108          PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS (2017–2019)
TABLE 109          SERVICE LAUNCHES (2017–2019)
TABLE 110          MERGERS & ACQUISITIONS (2017–2019)
TABLE 111          EXPANSIONS (2017–2019)

LIST OF FIGURES

FIGURE 1            DRUG DISCOVERY SERVICES MARKET SEGMENTATION
FIGURE 2            RESEARCH DESIGN
FIGURE 3            BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION
FIGURE 4            BOTTOM-UP APPROACH
FIGURE 5            TOP-DOWN APPROACH
FIGURE 6            DATA TRIANGULATION METHODOLOGY
FIGURE 7            DRUG DISCOVERY SERVICES MARKET, BY PROCESS,
2020 VS. 2025 (USD MILLION)
FIGURE 8            DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2020 VS. 2025 (USD MILLION)
FIGURE 9            DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2020 VS. 2025 (USD MILLION)
FIGURE 10          DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
2020 VS. 2025 (USD MILLION)
FIGURE 11          DRUG DISCOVERY SERVICES MARKET, BY REGION, 2020 VS. 2025 (USD MILLION)
FIGURE 12          INCREASING R&D EXPENDITURE IN THE PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY TO DRIVE MARKET GROWTH
FIGURE 13          SMALL-MOLECULE DRUGS TO ACCOUNT FOR THE LARGEST SHARE OF
THE NORTH AMERICAN DRUG DISCOVERY SERVICES MARKET IN 2020
FIGURE 14          CHINA TO REGISTER THE HIGHEST GROWTH IN THE DRUG DISCOVERY SERVICES MARKET DURING THE FORECAST PERIOD
FIGURE 15          DRUG DISCOVERY SERVICES MARKET: DRIVERS, RESTRAINTS,
AND OPPORTUNITIES
FIGURE 16          R&D SPENDING OF PHRMA MEMBER COMPANIES, 2001–2017 (USD BILLION)
FIGURE 17          ACTIVE PHARMACEUTICAL PIPELINE, JANUARY 2009–JANUARY 2019
FIGURE 18          NUMBER OF ORPHAN INDICATIONS APPROVED IN THE US (2010–2017)
FIGURE 19          NUMBER OF REGISTERED STUDIES (2005–2017)
FIGURE 20          AVERAGE COST TO DEVELOP ONE NEW APPROVED DRUG—INCLUDING
THE COST OF FAILURES
FIGURE 21          R&D PIPELINE, BY THERAPY GROUP, 2018 & 2019
FIGURE 22          TOTAL NUMBER OF CLINICAL TRIALS FOR ONCOLOGY,
BY REGION (AS OF DECEMBER 2019)
FIGURE 23          TOTAL NUMBER OF CLINICAL TRIALS: GLOBAL VS. NORTH AMERICA
FIGURE 24          NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET SNAPSHOT
FIGURE 25          US: PIPELINE SPLIT OF PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES,
BY PHASE (JANUARY 2019)
FIGURE 26          UK: PHARMACEUTICAL R&D EXPENDITURE, 2013–2017
FIGURE 27          SPAIN: PHARMACEUTICAL R&D EXPENDITURE, 2011–2017
FIGURE 28          APAC: DRUG DISCOVERY SERVICES MARKET SNAPSHOT
FIGURE 29          DRUG DISCOVERY SERVICES MARKET SHARE (2018)
FIGURE 30          GLOBAL DRUG DISCOVERY SERVICES MARKET: COMPETITIVE
LEADERSHIP MAPPING (2018)

FIGURE 31          LABCORP: COMPANY SNAPSHOT (2018)
FIGURE 32          EUROFINS SCIENTIFIC SE: COMPANY SNAPSHOT (2018)
FIGURE 33          CHARLES RIVER LABORATORIES INTERNATIONAL: COMPANY SNAPSHOT (2018)
FIGURE 34          EVOTEC SE: COMPANY SNAPSHOT (2018)
FIGURE 35          THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2018)
FIGURE 36          SYNGENE: COMPANY SNAPSHOT (2018)
FIGURE 37          JUBILANT LIFESCIENCES: COMPANY SNAPSHOT (2018)
FIGURE 38          GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2018)
FIGURE 39          PIRAMAL ENTERPRISES LIMITED: COMPANY SNAPSHOT (2018)

当レポートのプレスリリースは発行されておりません。